000 01655 a2200469 4500
005 20250515211931.0
264 0 _c20110812
008 201108s 0 0 eng d
022 _a1618-7601
024 7 _a10.1007/s10198-010-0224-8
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBoye, Kristina S
245 0 0 _aUtilities and disutilities for attributes of injectable treatments for type 2 diabetes.
_h[electronic resource]
260 _bThe European journal of health economics : HEPAC : health economics in prevention and care
_cJun 2011
300 _a219-30 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAge Factors
650 0 4 _aAged
650 0 4 _aBody Mass Index
650 0 4 _aDiabetes Mellitus, Type 2
_xdrug therapy
650 0 4 _aDrug Administration Routes
650 0 4 _aDrug Administration Schedule
650 0 4 _aFemale
650 0 4 _aHealth Status
650 0 4 _aHumans
650 0 4 _aHypoglycemic Agents
_xadministration & dosage
650 0 4 _aInterviews as Topic
650 0 4 _aMale
650 0 4 _aMental Health
650 0 4 _aMiddle Aged
650 0 4 _aQuality of Life
650 0 4 _aSex Factors
650 0 4 _aSocioeconomic Factors
700 1 _aMatza, Louis S
700 1 _aWalter, Kimberly N
700 1 _aVan Brunt, Kate
700 1 _aPalsgrove, Andrew C
700 1 _aTynan, Aodan
773 0 _tThe European journal of health economics : HEPAC : health economics in prevention and care
_gvol. 12
_gno. 3
_gp. 219-30
856 4 0 _uhttps://doi.org/10.1007/s10198-010-0224-8
_zAvailable from publisher's website
999 _c19591195
_d19591195